-
Notifications
You must be signed in to change notification settings - Fork 1
New issue
Have a question about this project? Sign up for a free GitHub account to open an issue and contact its maintainers and the community.
By clicking “Sign up for GitHub”, you agree to our terms of service and privacy statement. We’ll occasionally send you account related emails.
Already on GitHub? Sign in to your account
UNC Kinome Scan #17
Comments
@mbhebhe Can I just confirm the results. OSM-S-137 has a POC of 75 against PfCDPK1 but also similar activity against 50 other kinases? |
@drc007 Thanks for pointing that out. I hadn't realised that the structures had been switched. I will contact them to confirm. |
Also interesting to note the left hand side of https://en.wikipedia.org/wiki/Quizartinib (FLT3 inhibitor in development) looks a tad bit like our morpholine compound! @mbhebhe @drc007 @mattodd |
Hi @Skame161 - here's the kinome scan I was mentioning. Compare and contrast with the predictive modelling that was done..? |
@mattodd Thanks Hi @mbhebhe -- Relatively new to the project and trying to get a handle on what the data means for which kinases OSM-S-106 is active against. Do we have a summary somewhere that I might have missed and do we know how these compare with which kinases came up in predictive modelling? Thanks and regards. |
Hi @Skame161 we only have the data that they gave us, they are in my ELN (https://au-mynotebook.labarchives.com/share/Tha%2520OSM%2520Series%25203/NTU2LjR8MjcwNjkvNDI4LTIwNjUvVHJlZU5vZGUvMzU3MTU3NzYxMHwxNDEyLjM5OTk5OTk5OTk5OTk=) |
OK, thank you. I'll take a look. |
We sent OSM-S-106, 137 and 126 to UNC Chapel Hill (David Drewry) for a Kinome Scan.
The preliminary results can be found on here.
OSM-S-106: Only 2 non-mutant human kinases with POC<10 at the 1 micromolar screening concentration (TYK2 and MAP3K19). A number of other kinases have POC<20. Interestingly, PfCDPK1 has POC=11, so perhaps a decent inhibitor.
OSM-S-137: WEE1 has POC= 0. My guess is that this is a false positive.
OSM-S-126: Data suggests this is a relatively narrow spectrum human FLT3 inhibitor.
They are currently doing the Kd determinations. The potentially potent and selective FLT3 compound is cool. They are intrigued by the TYK2 pseudokinase result. If the Kd confirms they would like to pursue this a little more carefully. (MHT (2/10/19): it has interesting biology, e.g. here and here, but, I think, no inhibitor?)
OSM-S-106: NC1=C2C(C=C(C3=CC(S(=O)(N)=O)=CC=C3)S2)=NC=N1
OSM-S-137: O=S(C1=CC(C2=CC3=NC=NC(N4CCN(CC5=CC=C(F)C=C5)CC4)=C3S2)=CC=C1)(N)=O
OSM-S-126: C12=NC=NC(N3CCOCC3)=C1SC(C4=CC=CC=C4)=C2
The text was updated successfully, but these errors were encountered: